Immix Biopharma (IMMX) EBT (2021 - 2026)

Immix Biopharma has disclosed EBT across 6 years of filings, most recently posting -$10.1 million for Q1 2026.

• EBT for Q1 2026 came in at -$10.1 million, down 122.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$35.0 million (down 4542.14% YoY), and the FY2025 annual result was -$29.4 million, down 1806.04% from the prior year.
• EBT came in at -$10.1 million for Q1 2026 at Immix Biopharma, up from -$10.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $15.3 million in Q4 2024 to a low of -$10.7 million in Q4 2025.
• The 5-year median for EBT is -$4.4 million (2024), against an average of -$3.8 million.
• Across the five-year window, EBT tumbled 654.03% in 2022 and surged 397.51% in 2024, its largest moves.
• Immix Biopharma's EBT stood at -$3.8 million in 2022, then tumbled by 35.65% to -$5.1 million in 2023, then soared by 397.51% to $15.3 million in 2024, then plunged by 169.72% to -$10.7 million in 2025, then grew by 5.52% to -$10.1 million in 2026.
• The last three EBT figures came in at -$10.1 million (Q1 2026), -$10.7 million (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.